| Psoriasis vulgaris
Siliq vs Tazorac
Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.Deep comparison between: Siliq vs Tazorac with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTazorac has a higher rate of injection site reactions vs Siliq based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tazorac but not Siliq, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Siliq
Tazorac
At A Glance
Subcutaneous
Every 2 weeks
IL-17RA antagonist
Topical
Daily
Retinoid
Indications
- Psoriasis vulgaris
- Psoriasis vulgaris
- Acne Vulgaris
Dosing
Psoriasis vulgaris 210 mg subcutaneously at Weeks 0, 1, and 2 followed by 210 mg every 2 weeks.
Psoriasis vulgaris Apply a thin film (2 mg/cm2) of 0.05% cream once daily in the evening to psoriatic lesions only; increase to 0.1% if tolerated and medically indicated.
Acne Vulgaris Apply a thin layer (2 mg/cm2) of 0.1% cream once daily in the evening to affected facial skin areas after gentle cleansing and drying.
Contraindications
- Crohn's disease
- Clinically significant hypersensitivity to brodalumab or to any of the excipients
- Pregnancy (retinoids may cause fetal harm)
- Known hypersensitivity to any component of TAZORAC Cream
Adverse Reactions
Most common (>=1%) Arthralgia (4.7%), headache (4.3%), fatigue (2.6%), diarrhea (2.2%), oropharyngeal pain (2.1%), nausea (1.9%), myalgia (1.7%), injection site reactions (1.5%), influenza (1.3%), neutropenia (1.0%), tinea infections (1.0%).
Serious Suicidal ideation and behavior (0.37 per 100 subject-years), infections including fungal infections, neutropenia grade >=3.
Postmarketing Hypersensitivity reactions, anaphylaxis including anaphylactic shock, pruritus, rashes, eczema, urticaria, dermatitis, eczematous eruptions (atopic dermatitis-like eruptions).
Most common (>=10%) Psoriasis: pruritus, erythema, burning; Acne: desquamation, dry skin, erythema, burning sensation
Serious Embryofetal toxicity, photosensitivity and risk of sunburn
Postmarketing Blister, dermatitis, urticaria, skin exfoliation, skin discoloration (hyperpigmentation or hypopigmentation), swelling at or near application sites, pain
Pharmacology
Brodalumab is a human monoclonal IgG2 antibody that selectively binds to IL-17RA and inhibits its interactions with IL-17 family cytokines (IL-17A, IL-17F, IL-17C, IL-17A/F heterodimer, IL-25), thereby blocking IL-17 cytokine-induced pro-inflammatory responses.
Tazarotene is a retinoid prodrug converted by esterase hydrolysis to tazarotenic acid, which binds retinoic acid receptors RAR-beta and RAR-gamma with relative selectivity and may modify gene expression in psoriatic and acne-affected skin.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Siliq
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
No coverage data available for Tazorac.
UnitedHealthcare
Siliq
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (1/8)
No coverage data available for Tazorac.
Humana
Siliq
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
No coverage data available for Tazorac.
Coverage data sourced from MMIT. Updated monthly.
Savings
$50/momo
Siliq Solutions Instant Savings Program - Non-covered benefitCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Tazorac.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TazoracView full Tazorac profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.